Manchester Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Manchester Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-65,742	Closed	-$1.32M	–	1135
2021 Q3	$1.32M	Hold	65,742	–	–	0.18%	77
2021 Q2	$2.45M	Hold	65,742	–	–	0.34%	37
2021 Q1	$1.68M	Hold	65,742	–	–	0.25%	59
2020 Q4	$1.45M	Buy	65,742 +7,285	+12%	+$160K	0.22%	67
2020 Q3	$1.05M	Buy	58,457 +11,314	+24%	+$234K	0.16%	82
2020 Q2	$1.2M	Hold	47,143	–	–	0.16%	75
2020 Q1	$866K	Hold	47,143	–	–	0.14%	93
2019 Q4	$1.04M	Buy	47,143 +28,286	+150%	+$569K	0.11%	104
2019 Q3	$271K	Hold	18,857	–	–	0.03%	212
2019 Q2	$297K	Hold	18,857	–	–	0.04%	205
2019 Q1	$276K	Hold	18,857	–	–	0.04%	203
2018 Q4	$231K	Hold	18,857	–	–	0.04%	196
2018 Q3	$288K	Hold	18,857	–	–	0.04%	189
2018 Q2	$231K	Hold	18,857	–	–	0.04%	199
2018 Q1	$180K	Buy	+18,857	New	+$203K	0.03%	213

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Manchester Capital Management's DRNA Position: Q4 2021 in Review

Manchester Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 65,742 shares — an estimated $1.32M sold.

Manchester Capital Management first reported a position in DRNA in Q1 2018 and held it in 15 quarters. The position peaked at $2.45M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Manchester Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Manchester Capital Management sold 65,742 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.32M.
Manchester Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 15 quarters.
Manchester Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.45M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Manchester Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.